Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


01.05.2017

2 BJU Int
1 Br J Cancer
2 Cancer
1 Clin Cancer Res
1 Curr Treat Options Oncol
1 Endocrinology
2 Eur Urol
1 Int J Cancer
1 Int J Oncol
1 Int J Radiat Oncol Biol Phys
3 J Clin Oncol
1 J Urol
1 Nat Rev Urol
2 Oncol Rep
1 PLoS Genet
1 Prostate
7 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. PROTOPAPA E, van der Meulen J, Moore CM, Smith SC, et al
    Patient Reported Outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13896.
    PubMed     Text format     Abstract available

  2. PARSONS JK, Pierce JP, Mohler J, Paskett E, et al
    The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13890.
    PubMed     Text format     Abstract available


    Br J Cancer

  3. TRIGGIANI L, Alongi F, Buglione M, Detti B, et al
    Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
    Br J Cancer. 2017 Apr 27. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Cancer

  4. WALLNER LP, Jacobsen SJ
    Prostate cancer in black men: Is it time for personalized screening approaches?
    Cancer. 2017 Apr 24. doi: 10.1002/cncr.30685.
    PubMed     Text format    

  5. TSODIKOV A, Gulati R, de Carvalho TM, Heijnsdijk EAM, et al
    Is prostate cancer different in black men? Answers from 3 natural history models.
    Cancer. 2017 Apr 24. doi: 10.1002/cncr.30687.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  6. GUEDES L, Almutairi F, Haffner MC, Rajoria G, et al
    Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.0257.2017.
    PubMed     Text format     Abstract available


    Curr Treat Options Oncol

  7. FAKHREJAHANI F, Madan RA, Dahut WL
    Management Options for Biochemically Recurrent Prostate Cancer.
    Curr Treat Options Oncol. 2017;18:26.
    PubMed     Text format     Abstract available


    Endocrinology

  8. RECOUVREUX MV, Wu B, Gao AC, Zonis S, et al
    Androgen receptor regulation of local growth hormone in prostate cancer cells.
    Endocrinology. 2017 Apr 21. doi: 10.1210/en.2016-1939.
    PubMed     Text format     Abstract available


    Eur Urol

  9. GRUMMET JP, Plass K, N'Dow J
    Prostate Cancer Management in an Ageing Population.
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30290.
    PubMed     Text format    

  10. WALSH PC
    The Search for the Missing Heritability of Prostate Cancer.
    Eur Urol. 2017 Apr 22. pii: S0302-2838(17)30283.
    PubMed     Text format     Abstract available


    Int J Cancer

  11. POUNIS G, Tabolacci C, Costanzo S, Cordella M, et al
    Reduction by coffee consumption of prostate cancer risk: Evidence from the Moli-sani cohort and cellular models.
    Int J Cancer. 2017 Apr 24. doi: 10.1002/ijc.30720.
    PubMed     Text format     Abstract available


    Int J Oncol

  12. LU S, Dong Z
    Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
    Int J Oncol. 2017 Apr 19. doi: 10.3892/ijo.2017.3964.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  13. RODDA S, Tyldesley S, Morris WJ, Keyes M, et al
    ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017 Jan 6. pii: S0360-3016(17)30008.
    PubMed     Text format     Abstract available


    J Clin Oncol

  14. LECARPENTIER J, Silvestri V, Kuchenbaecker KB, Barrowdale D, et al
    Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
    J Clin Oncol. 2017 Apr 27:JCO2016694935. doi: 10.1200/JCO.2016.69.4935.
    PubMed     Text format     Abstract available

  15. LOEB S, Folkvaljon Y, Damber JE, Alukal J, et al
    Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
    J Clin Oncol. 2017;35:1430-1436.
    PubMed     Text format     Abstract available

  16. VIRGO KS, Basch E, Loblaw DA, Oliver T, et al
    Second-Line Hormonal Therapy for Men With Chemotherapy-Naive, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
    J Clin Oncol. 2017 Apr 25:JCO2017728030. doi: 10.1200/JCO.2017.72.8030.
    PubMed     Text format     Abstract available


    J Urol

  17. GOLAN R, Bernstein AN, McClure TD, Sedrakyan A, et al
    Partial gland treatment of prostate cancer utilizing high-intensity focused ultrasound in the primary and salvage setting: a systematic review.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54786-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  18. STONE L
    Prostate cancer: Antagonizing AR: MYC affects transcription.
    Nat Rev Urol. 2017 Apr 25. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    Oncol Rep

  19. YIN B, Liu Z, Wang Y, Wang X, et al
    RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells.
    Oncol Rep. 2017 Apr 19. doi: 10.3892/or.2017.5585.
    PubMed     Text format     Abstract available

  20. BAI S, Chen T, Yu X, Luo M, et al
    The specific killing effect of matrine on castration-resistant prostate cancer cells by targeting the Akt/FoxO3a signaling pathway.
    Oncol Rep. 2017;37:2819-2828.
    PubMed     Text format     Abstract available


    PLoS Genet

  21. JIN X, Wang J, Gao K, Zhang P, et al
    Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
    PLoS Genet. 2017;13:e1006748.
    PubMed     Text format     Abstract available


    Prostate

  22. SCHALLY AV, Block NL, Rick FG
    Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.
    Prostate. 2017 Apr 27. doi: 10.1002/pros.23360.
    PubMed     Text format     Abstract available


    Urology

  23. POELAERT F, Verbaeys C, Rappe B, Kimpe B, et al
    Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective LoMP Trial.
    Urology. 2017 Apr 20. pii: S0090-4295(17)30372.
    PubMed     Text format     Abstract available

  24. JUE JS, Barboza MP, Prakash NS, Venkatramani V, et al
    Re-Examining PSA Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy.
    Urology. 2017 Apr 18. pii: S0090-4295(17)30368.
    PubMed     Text format     Abstract available

  25. XIA L, Zeh R, Mizelle J, Newton A, et al
    Near-Infrared Intraoperative Molecular Imaging Can Identify Metastatic Lymph Nodes in Prostate Cancer.
    Urology. 2017 Apr 21. pii: S0090-4295(17)30386.
    PubMed     Text format     Abstract available

  26. KARATZAS AD, Zachos I, Mitrakas L, Dimitropoulos K, et al
    Generalized Lymphadenopathy of Prostate Adenocarcinoma Origin. A Case Series.
    Urology. 2016;91:e3-4.
    PubMed     Text format     Abstract available

  27. DASON S, Allard CB, Wright I, Shayegan B, et al
    Transurethral Resection of the Prostate Biopsy of Suspected Anterior Prostate Cancers Identified by Multiparametric Magnetic Resonance Imaging: A Pilot Study of a Novel Technique.
    Urology. 2016;91:129-35.
    PubMed     Text format     Abstract available

  28. CANTIELLO F, Gangemi V, Cascini GL, Calabria F, et al
    Diagnostic Accuracy of 64Cu-PSMA PET/CT for Primary Lymph Node Staging of Intermediate to High Risk Prostate Cancer: Our Preliminary Experience.
    Urology. 2017 Apr 21. pii: S0090-4295(17)30385.
    PubMed     Text format     Abstract available

  29. QUINTANA L, Ward A, Gerrin SJ, Genega EM, et al
    Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy.
    Urology. 2016;91:143-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: